NCT07381985Enrolling by invitation
Strategy for Management of Patients With Hereditary Cancer Syndromes (HCS) in a Rural Environment
Source: ClinicalTrials.gov · Last updated 2 Feb 2026
Brief summary (registry, in English)
This study aims to improve cancer prevention and surveillance adherence in patients with Hereditary Cancer Syndromes (HCS), particularly those living in rural areas. The study will evaluate whether enrolling HCS patients in a longitudinal clinical program with individualized care plans and regular follow-up improves adherence to guideline-recommended cancer screening and risk-reduction strategies. Secondary aims include assessing the program's impact on patient distress and perceived care coordination. The study will enroll 200 adults with known pathogenic germline mutations who were previously seen at the UVM Medical Center genetics clinic. Participants will complete surveys at baseline, 12, and 24 months to assess adherence, distress, and care coordination. Findings from this study will inform future efforts to reduce gaps in hereditary cancer care delivery, especially for rural populations.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 8 May 2025
- Start date
- 29 Dec 2023
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- University of Vermont Medical Center
- Diseases
- Ovarian cancer
- NCT number
- NCT07381985
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 29 Dec 2023 to the primary completion date, 1 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- Patients who tested positive for a germline pathogenic variant associated with cancer risk \< 1 year ago are not eligible.
Who the study is looking for
- Patients of all genders must be ≥ 18 years of age.
- Patients must have a known pathogenic germline variant in a cancer risk gene that was identified by a CLIA-approved lab more than one year ago.
- Patients must be able to accurately provide self-report data (i.e., per clinical judgment, cognitive function is intact).
- Patients must be able to complete questionnaires in English.
- Patients must have the ability to provide informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Vermont Medical Center Coordinator of this site? Confirm its status | Burlington | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.